1. Home
  2. JANX vs TXG Comparison

JANX vs TXG Comparison

Compare JANX & TXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$16.51

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo 10x Genomics Inc.

TXG

10x Genomics Inc.

HOLD

Current Price

$17.77

Market Cap

1.6B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
JANX
TXG
Founded
2017
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
JANX
TXG
Price
$16.51
$17.77
Analyst Decision
Strong Buy
Buy
Analyst Count
12
13
Target Price
$62.00
$14.73
AVG Volume (30 Days)
2.3M
3.3M
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,000,000.00
$641,814,000.00
Revenue This Year
N/A
$4.50
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.92
52 Week Low
$15.51
$6.78
52 Week High
$71.71
$20.34

Technical Indicators

Market Signals
Indicator
JANX
TXG
Relative Strength Index (RSI) 29.81 57.17
Support Level $15.51 $17.06
Resistance Level $35.34 $19.29
Average True Range (ATR) 1.91 1.08
MACD -1.87 -0.10
Stochastic Oscillator 4.34 48.84

Price Performance

Historical Comparison
JANX
TXG

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

About TXG 10x Genomics Inc.

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Share on Social Networks: